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Prostate-specific antigen (PSA), which is a serine protease with
trypsin- and chymotrypsin-like activities (Lilja, 1985), is a useful
serum marker in the management of prostate cancer (Stamey et al,
1987; Catalona et al, 1991; Oesterling, 1991). However, there is a
growing body of evidence indicating that PSA may also play a role
in a variety of other cancers (Levesque et al, 1995a; Diamandis,
1996), including breast (Giai et al, 1995; Yu et al, 1995a, 1996a,
1998; Lehrer et al, 1996; Melegos et al, 1997) and ovarian cancer
(Yu et al, 1995b). In breast cancer tissues, the levels of PSA
protein have been shown to be correlated with the levels of the
progesterone receptor (PgR), rather than with those of the
oestrogen receptor (ER) (Yu et al, 1994a). In addition, the expres-
sion of PSA in breast cancer appeared to be under control of
androgens and progestins (Yu et al, 1994b; Zarghami et al, 1997),
and it has been suggested that PSA may act as a negative growth
regulator in hormone-dependent breast cancer (Lai et al, 1996).
Insulin-like growth factor I and II (IGF-I and -II) are known as
potent mitogens for breast cancer cells (Osborne et al, 1989; Cullen
et al, 1990). Binding of IGFs to their binding proteins (IGFBPs) can
reduce their mitogenic response (Figueroa and Yee, 1992). PSA has
been shown to be able to cleave IGFBP-3 (Cohen et al, 1992),
suggesting that PSA may increase the bioavailability of IGFs
through (local) digestion of IGFBP-3 (Kanety et al, 1993; Cohen et
al, 1994) thus enhancing breast tumour growth. Human breast
tumour biopsies contain a variety of IGFBPs (Manni et al, 1994; Yu
et al, 1996b), and their levels may be of prognostic significance (Yee
et al, 1994). Treatment of breast cancer patients with tamoxifen
reduced serum levels of IGF-I and increased the levels of some, but
not all, IGFBPs (Pollak et al, 1990; Lonning et al, 1992; Lahti et al,
1994). These results suggest that tamoxifen may regulate IGF action
at the cellular level such that tumour growth promotion is inhibited.
However, disruption of the interaction between IGFs and IGFBPs
through proteolysis by secreted serine proteases (Campbell et al,
1992; Lalou et al, 1994), including PSA (Cohen et al, 1992), may
locally disturb the balance, resulting in increased tumour cell growth
through the release of active IGFs (Blat et al, 1994).
In the present study, we have investigated a possible relation-
ship between the tumour level of PSA and response and (progres-
sion-free) survival in a large series of 434 patients with recurrent
breast cancer who received tamoxifen therapy. In addition, we
have studied the relationship between the tumour level of PSA and
the length of relapse-free and overall survival in 1516 patients
with primary breast cancer.
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Summary Prostate-specific antigen (PSA) is a serine protease which may play a role in a variety of cancer types, including breast cancer. In
the present study, we evaluated whether the level of PSA in breast tumour cytosol could be associated with prognosis in primary breast cancer,
or with response to tamoxifen therapy in recurrent disease. PSA levels were determined by enzyme-linked immunosorbent assay (ELISA) in
breast tumour cytosols, and were correlated with prognosis in 1516 patients with primary breast cancer and with response to first-line tamoxifen
therapy in 434 patients with recurrent disease. Relating the levels of PSA with classical prognostic factors, low levels were more often found in
larger tumours, tumours of older and post-menopausal patients, and in steroid hormone receptor-negative tumours. There was no significant
association between the levels of PSA with grade of differentiation or the number of involved lymph nodes. In patients with primary breast
cancer, PSA was not significantly related to the rate of relapse, and a positive association of PSA with an improved survival could be attributed
to its relationship to age. In patients with recurrent breast cancer, a high level of PSA was significantly related to a poor response to tamoxifen
therapy, and a short progression-free and overall survival after start of treatment for recurrent disease. In Cox multivariate analyses for
response to therapy and for (progression-free) survival, corrected for age/menopausal status, disease-free interval, site of relapse and steroid
hormone receptor status, PSA was an independent variable of poor prognosis. It is concluded that the level of PSA in cytosols of primary breast
tumours might be a marker to select breast cancer patients who may benefit from systemic tamoxifen therapy.
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MATERIALS AND METHODS
Patients and tissues
Analysis of relapse-free and overall survival was performed on
1516 patients with primary operable breast cancer diagnosed
between 1978 and 1990. Inclusion criteria for patients, whose
tumour or cytosol samples were stored in our tumour bank (liquid
nitrogen), were as described previously (Van Putten et al, 1996).
Median age of the patients at the time of surgery (modified
mastectomy, 757 patients; breast conserving lumpectomy, 759
patients) was 56 years (range 24–89 years). Radiotherapy was
given to 87% of the patients: on the breast/thoracic wall in 1083
patients and/or on the axilla in 511 patients, and/or on lymph node
areas other than the axilla in 621 patients. Adjuvant chemotherapy
(mainly CMF; cyclophosphamide, methotrexate, 5-fluorouracil)
was given to 245 patients, whereas 100 patients received adjuvant
hormonal therapy either alone (83 patients) or in combination with
CMF (17 patients). All patients were routinely examined every
3–6 months during the first 5 years of follow-up, and once a year
thereafter. Of the 1516 patients included in the study for analysis
of relapse-free and overall survival, 718 (47%) showed evidence
of relapse during follow-up and count as failures in the analysis for
relapse-free survival. Eighty-six patients died without evidence of
disease and were censored at last follow-up in the analysis for
relapse-free survival. Four hundred and ninety-seven patients died
after a previous relapse. A total of 583 (86 + 497) patients (38%)
were considered as failures in the analysis for overall survival. The
median follow-up of patients alive (n = 933) is 85 months (range
13–202 months). The characteristics of the patients with respect to
tumour size, lymph node status, differentiation grade of the
tumour, age and menopausal status, and ER and PgR at time of
surgery are listed in Table 1.
In analysis of response to first-line tamoxifen therapy for recur-
rent disease, 347 out of 718 patients who showed a relapse, as
reported above, were evaluable according to the following criteria:
the patients must have developed recurrent disease and be
subjected to first-line tamoxifen therapy (40 mg day–1).
Furthermore, the patients must not have had adjuvant hormonal
therapy, neoadjuvant therapy, or prior chemotherapy for advanced
disease. This subset was extended with another 87 patients using
the same inclusion criteria, to establish a larger series of metastatic
breast cancer patients (434 patients) who received tamoxifen
therapy as first-line treatment for recurrent disease.
The median age of the patients at start of treatment for advanced
disease with tamoxifen was 61 years (range 28–87 years). Twenty-
three per cent (n = 100) of the patients were premenopausal, and
Table 1 Relationship of PSA to patient and tumour characteristics
PSA (pg mg–1 protein)
≤ 7.25 > 7.25–20.3 > 20.3–76 > 76
Characteristic na (%) (%) (%) (%) P-value
All patients 1516 25 25 25 25
Age (years) < 0.0001b
≤ 40 189 18 27 24 31
40–55 547 22 20 28 30
56–70 522 27 27 23 22
> 70 258 32 29 24 16
Menopausal status
Premenopausal 618 18 22 27 33
Post-menopausal 898 30 27 24 20 0.0001c
Tumour size < 0.001c
T1 626 22 25 26 27
T2 720 27 25 23 25
T3/4 170 29 23 28 19
Nodal status nsb
N0 708 23 25 26 26
N1–3 387 26 25 22 27
N> 3 407 28 24 27 21
Grade nsb
Well 26 27 19 19 35
Moderate 254 21 23 28 27
Poor 860 27 25 24 24
ER positive
No 329 35 25 23 16
Yes 1185 22 25 25 27 nsa
PgR positive
No 426 35 24 26 15
Yes 1054 21 25 25 29 <0.0001a
aBecause of missing values, the numbers do not always add up to 1516. bSpearman rank correlation. cWilcoxon rank sum/Kruskal–Wallis test, including a
Willcoxon-type test for trend across ordered groups.890 JA Foekens et al
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77% (n = 334) post-menopausal. The dominant site of disease was
visceral in 157 patients, bone in 222 patients, and soft tissue in 55
patients. Twenty-nine patients (7%) had metastatic disease (M1
patients) at time of primary surgery. After primary surgery, 83
patients (19%) had received systemic adjuvant chemotherapy
(CMF, 65 patients; FAC; 5-fluorouracil, adriamycin, cyclophos-
phamide, 18 patients). During their life with metastatic disease,
60.4% of the patients were subsequently treated with one or more
additional hormonal treatments (mostly progestins) after progres-
sion on the first-line tamoxifen treatment. After occurrence of
resistance to hormonal therapy, 226 patients (52.1%) received
additional chemotherapy (mainly CMF). Ninety-two patients are
still alive at time of analysis with a median follow-up of 81 months
(range 19–149 months), and 342 patients have died with a median
survival time of 41 months (range 3–166 months). During follow-
up after start of first-line endocrine therapy, 91% of the patients
(395 out of 434) developed tumour progression with a median time
to progression of 163 days (range 18 days to >9 years). During
endocrine therapy, patients were assessed at the outpatient clinic
on average once every 6 weeks; during long-term remission, up to
once every 12 weeks. Response to therapy was assessed by stan-
dard criteria for objective response (complete and partial remis-
sion). Patients with stable disease (SD; no change for more than 6
months) have a survival probability similar to those with a partial
remission (Foekens et al, 1994). Response to treatment was
defined as a patient having either an objective response or a
prolonged SD with a time to treatment failure of more than 6
months, as defined previously (Nicholson et al, 1989; Ravdin et al,
1992; Foekens et al, 1994, 1995). In case of doubt, the worst cate-
gory of response was chosen. Of the 434 patients who received
tamoxifen therapy as first-line treatment for recurrent disease, 221
(51%) responded (55 objective response, 166 stable disease). Of
the 213 patients who did not respond (49%), 45 patients had no
change of disease for a period equal to or shorter than 6 months,
and 168 patients showed progressive disease.
Assay of PSA, ER and PgR
Tumour tissues were stored in liquid nitrogen and pulverized in the
frozen state with a microdismembrator as recommended by the
European Organization for Research and Treatment of Cancer
(EORTC) for processing of breast tumour tissue for cytosolic ER
and PgR determinations (EORTC Breast Cancer Cooperative
Group, 1980). The resulting tissue powder was suspended in
EORTC receptor buffer (10 mM dipotassium hydrogen phosphate
buffer, containing 1.5 mM dipotassium chloride EDTA, 3 mM
sodium azide, 10 mM monothioglycerol, and 10% v/v glycerol,
pH 7.4). The suspension was centrifuged for 30 min at 100 000 g
to obtain the supernatant fraction (cytosol). ER and PgR levels
were determined by ligand binding assay or with enzyme
immunoassay as described previously (Foekens et al, 1989). The
cut-off point used to classify tumours as ER or PgR positive and
negative was 10 fmol mg–1 cytosolic protein.
Cytosolic PSA levels were determined in duplicate with a
highly sensitive and specific immunofluorometric procedure,
which has previously been described in detail (Ferguson et al,
1996). PSA concentrations in the tumour samples are expressed as
pg mg–1 cytosolic protein. PSA is a very stable molecule and its
concentration in breast tumour cytosols does not change when the
samples are kept frozen at –20°C or lower. Consequently, there
were no statistically significant differences in the levels of PSA in
relation to the duration of storage of the samples.
Statistics
The strength of the associations of PSA with other variables was
tested with non-parametric tests: for categorical variables, the
Wilcoxon rank–sum or Kruskal–Wallis test, including a Wilcoxon-
type test for trend across ordered groups when appropriate and the
Spearman rank correlation (rs) for continuous variables. In patients
with recurrent breast cancer who received tamoxifen as first-line
Table 2 Cox multivariate analysis for relapse-free survival for the basic
modelc
Variable RHRa 95% Clb P-value
Age and menopausal status < 0.0001
Age premenopausal 0.66 0.56–0.78
Age post-menopausal 0.90 0.81–1.01
Post- vs premenopausal 1.82 1.37–2.41
Tumour size <0.0001
T2 vs T1 1.44 1.21–1.72
T3/4 vs T1 1.89 1.47–2.41
Nodal status
N1–3 vs N0 1.51 1.24–1.84 <0.0001
N>3 vs N0 2.96 2.45–3.57
+ ERd
Positive vs negativee 0.92 0.77–1.10 0.36
Continuous 0.99 0.95–1.02 0.45
+ PgRd
Positive vs negativee 0.86 0.73–1.02 0.08
Continuous 0.97 0.93–1.00 0.05
+ PSAd 0.97
Q2 vs Q1f 1.01 0.82–1.24
Q3 vs Q1 1.01 0.82–1.25
Q4 vs Q1 0.97 0.78–1.20
Continuous 1.01 0.97–1.05 0.69
aRHR, relative hazard rate. b95% Cl, 95% confidence interval. cThe basic
model included age/menopausal status, tumour size and nodal status.
dAdded separately to the basic model. eCut-off points used: 10 fmol mg–1
protein for both ER and PgR. f’Q1’: 0–7.25 pg mg–1 protein; ‘Q2’: >7.25–
20.3 pg mg–1 protein, ‘Q3’: >20.3–76 pg mg–1 protein; ‘Q4’: > 76 pg mg–1
protein.
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Figure 1 Distribution of PSA over 1516 primary breast tumour cytosols.
Arrow indicates the median value of 20.3 pg mg–1 proteinPSA in recurrent breast cancer 891
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treatment, in a test for trend in logistic regression analysis, and
Cox regression analysis, higher levels of PSA were associated
with a poor response, short progression-free and overall survival
after start of tamoxifen treatment respectively. This justified a
search for a cut-off point(s) to allow analysis of PSA as a categor-
ical variable. For this search, isotonic regression analysis, with all
three parameters as end point, was applied (Barlow et al, 1972).
Relapse-free and overall survival probabilities in primary breast
cancer and progression-free survival probabilities after start of
first-line therapy with tamoxifen in recurrent disease were calcu-
lated by the actuarial method of Kaplan and Meier (1958). Both
uni- and multivariate analysis was performed using the Cox
proportional hazard model. The associated likelihood ratio test
was used to test for differences. Logistic regression analysis was
applied for uni- and multivariate analysis of response.
RESULTS
PSA levels and relationships with patient and tumour
characteristics
The levels of PSA in primary tumours of patients which were
evaluable for analysis of relapse-free and overall survival ranged
from 0 to 50 000 pg mg–1 protein (median 20.3; mean ± s.d.
398 ± 2495 pg mg–1 protein). The distribution of the levels of PSA
in 1516 tumour cytosols is shown in Figure 1.
In Table 1, we present the percentage of tumours with PSA
levels divided in quartiles, in relation to patient and tumour char-
acteristics. Low levels of PSA were more often found in larger
tumours, and in tumours of older and post-menopausal patients.
There was no significant association between the levels of PSA
and ER (rs = 0.01; P > 0.05), grade of differentiation, or number of
involved lymph nodes. The levels of PSA were positively corre-
lated with those of PgR (rs = 0.16; P < 0.0001). PSA levels in PgR-
positive tumours were higher than in PgR-negative tumours,
with respective median values of 24.7 and 13.3 pg mg–1 protein
(P < 0.0001). Although the levels of PSA and ER were not signif-
icantly correlated when analysed by Spearman rank correlation,
PSA levels were higher in ER-positive tumours than in ER-nega-
tive tumours (median 22.5 and 12.4 pg mg–1 protein respectively;
P = 0.0001). In the four subgroups of tumours stratified by ER and
PgR status, PSA levels were lowest in the ER–/PgR– and
ER+/PgR– subgroups (11.7 and 16.0 pg mg–1 protein respec-
tively), and highest in the ER–/PgR+ and ER+/PgR+ subgroups
(22.4 and 24.9 pg mg–1 protein respectively). Thus, the data
suggest, in analogy with previous observations (Yu et al, 1994a,
1995a), that PSA is associated with PgR rather than with ER.
PSA and relapse-free and overall survival
In Cox univariate regression analysis including 1516 patients with
primary breast cancer, there was a statistically significant associa-
tion between log-transformed PSA values and the length of overall
survival (P = 0.009), but not with the length of relapse-free survival
(P = 0.42). The lack of a significant association between PSA and
relapse-free survival did not justify a search for cut-off points for
PSA. Therefore, the patients were divided into four groups with an
approximately equal number of patients based on their PSA levels.
In analysis for overall survival, patients with tumours containing
the 25% highest levels of PSA showed a favourable prognosis with
a relative hazard rate (RHR) and 95% confidence interval (95% CI)
of 0.69 (0.55–0.87) compared with those with the 25% lowest PSA
levels (P = 0.002). In additional analyses, after correction for age
only, PSA was not significantly associated with overall survival
(not shown). Therefore, the observed association of PSA with
improved overall survival in univariate analysis can be explained
by its negative relationship with age. In univariate analysis for
relapse-free survival, there was no significant difference (P = 0.26)
between the groups with the highest and lowest 25% PSA. Next,
the association of the levels of PSA with relapse-free survival, after
correction for classical prognostic factors, was studied. A basic
model was introduced which included age/menopausal status,
nodal status and tumour size (Table 2). When added separately to
the basic model as dichotomized or continuous variables, ER and
PgR were not or only marginally associated with an improved
relapse-free survival. In addition, PSA, when analysed both
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Figure 2 Progression-free (A) and overall survival after start of tamoxifen
treatment (B) in 434 patients with recurrent breast cancer who received
tamoxifen as first-line treatment as a function of the level of PSA. ‘High’,
> 125 pg mg–1 protein; ‘intermediate’, > 2.5–125 pg mg–1 protein; ‘low’,
0–2.5 pg mg–1 protein. Numbers in parentheses indicate the number of
failures/total number of patients in each group
Table 3 Relation of PSA status to response
PSA level
Responsea All patients Lowb Intermediateb Highb
No 213 13 154 46
Yes 221 32 159 30
Total 434 45 313 76
Fraction responders (%) 51 71 51 39
P < 0.01
aResponse, ‘yes’: objective response and stable disease (no change for
more than 6 months); ‘no’: progressive disease and no change for a period
equal or less than 6 months. b’Low’, 0–2.5 pg mg–1 protein; ‘intermediate’,
> 2.5–125 pg mg–1 protein; ‘high’, > 125 pg mg–1 protein.892 JA Foekens et al
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categorically and continuously, was not independently associated
with relapse-free survival (Table 2). Similar results were obtained
by multivariate analysis for overall survival (not shown), except
that ER and PgR significantly (P < 0.0001) added to the basic
model. When adjuvant hormonal and chemotherapy were added as
indicator variables to the multivariate model for relapse-free
survival, they were independently associated with decreased rates
of relapse (RHR = 0.69, P = 0.01; RHR = 0.61, P < 0.0001; respec-
tively). They did not affect the estimated regression coefficients of
PSA, and were therefore not included in the model shown in Table
2. Furthermore, also in subgroups of node-negative and node-
positive patients with or without adjuvant therapy, no associations
were found between PSA and relapse-free survival.
PSA and response to tamoxifen therapy
A total of 434 patients were included in the analysis of response to
first-line therapy with tamoxifen for recurrent disease as a function
of the level of PSA in the primary tumour. The median PSA level
in these tumours (23.0 pg mg–1 protein) was comparable to those in
the tumours of the 1516 patients who were analysed for relapse-
free and overall survival (20.3 pg mg–1 protein).
Of the 434 patients who were treated with tamoxifen for recurrent
disease, 221 (51%) responded. The median duration of response
was 15 months. In a test for trend using logarithmically transformed
PSA values, increasing levels of PSA were significantly associated
with a worse response, a poor progression-free survival, and a
short post-relapse survival after start of tamoxifen treatment (all,
P < 0.01). Isotonic regression analyses using these three end points
suggested the presence of two cut-off points. Therefore, in subse-
quent analyses using PSA as a categorical variable, the tumours
were classified as PSA-low (0–2.5 pg mg–1 protein; 45 patients),
PSA-intermediate (>2.5–125 pg mg–1 protein; 313 patients) and
PSA-high (>125 pg mg–1 protein; 76 patients). With increasing
levels of PSA, the response to tamoxifen significantly decreased
from 71% in the PSA-low group, to 51% in the PSA-intermediate
group, and to 39% in the PSA-high group (P < 0.01) (Table 3). The
fraction of complete and partial remissions decreased from 22% in
the PSA-low group, via 13% in the PSA-intermediate group, to 5%
in the PSA-high group. This decrease in objective response rates
with increasing levels of PSA was present both in patients with ER
levels ≤75 fmol mg–1 protein (41% of the tumours) and with ER
levels >75 fmol mg–1 protein (59% of the tumours). In the ER-low
group, the objective response rates decreased from 11%, via 9%, to
5%, whereas in the ER-high group the objective response rates
decreased from 31% in the PSA-low group, via 16% for the PSA-
intermediate group, to 5% for the PSA-high group.
Multivariate analysis for response was performed, including as
variables age and menopausal status, dominant site of relapse,
disease-free interval, ER and PgR (as continuous variables), and
PSA (intermediate compared with low; high compared with low).
Significant indicators of poor response in the final model were: a
short disease-free interval (≤1 year vs >1 year; P < 0.0001),
visceral metastasis (P = 0.04), low levels of ER (P < 0.0001), and
high levels of PSA. Compared with tumours with low PSA levels,
those with intermediate levels [odds ratio (OR) 0.41; 95% CI
0.20–0.83; P = 0.01] or high levels (OR 0.27; 95% CI 0.12–0.61;
P = 0.002) were significantly associated with a poor response to
tamoxifen therapy. Inclusion of adjuvant chemotherapy as indi-
cator variable in the multivariate regression models did not have
an effect on the estimated regression coefficients of PSA.
PSA and progression-free and overall survival after
start of tamoxifen treatment
In analogy with the relationship of PSA and response, the length of
progression-free survival on tamoxifen therapy decreased with
increasing PSA levels in the three subgroups of patients stratified
by PSA levels, respectively ranging from 11.0 months in PSA-low,
via 6.3 months in PSA-intermediate, to 5.5 months in tumours
with the highest PSA levels. The Kaplan–Meier curves for
progression-free survival and overall survival after start of tamox-
ifen therapy as a function of PSA status are shown in Figure 2A
and B respectively. In multivariate analyses for progression-free
survival and for overall survival after start of tamoxifen treatment,
PSA significantly contributed to the final models. In analysis for
progression-free survival, younger age, a short disease-free
interval, visceral metastasis, decreasing ER and PgR levels, and
intermediate (RHR 1.91; 95% CI 1.33–2.74; P < 0.001) and high
PSA levels (RHR 2.12; 95% CI 1.38–3.26; P < 0.001) were signif-
icant variables to predict an early progression. In overall survival
after start of tamoxifen treatment, PSA significantly (P < 0.001)
contributed to the final multivariate model, including disease-free
interval, visceral metastasis and ER. The respective relative hazard
rates for death for tumours with intermediate and high PSA levels,
compared with PSA-low tumours, were 1.98 (95% CI 1.33–2.93)
and 2.48 (95% CI 1.57–3.92).
DISCUSSION
For patients with breast cancer, it would be beneficial to have tools
available, in addition to the classical prognostic factors, which
could independently predict the rate of recurrence in primary
breast cancer and the efficacy of response to systemic therapy. In
patients with recurrent breast cancer, the presence of steroid recep-
tors in the primary tumour does not fully predict those patients
who are likely to benefit from endocrine therapy. About half of the
patients with steroid receptor-positive tumours do not respond
favourably to anti-oestrogen treatment. Therefore, biological
factors, other than ER and PgR, might be valuable for refinement
of therapy tailored to the patient’s need. The aberrant expression of
a specific cell biological parameter which is associated with a high
risk of relapse in primary breast cancer does not necessarily justify
the administration of adjuvant treatment. A particular form of
systems therapy may actually be inactive or even stimulate tumour
growth by triggering the cell biological factor. Therefore, biolog-
ical parameters should be evaluated both for their prognostic value
in primary and in metastatic breast cancer. One factor which may
be helpful in assessing prognosis in primary breast cancer is the
serine protease PSA (Yu et al, 1995a), whose expression is under
the control of steroid hormones, i.e. androgens and progestins (Yu
et al, 1994b; Zarghami et al, 1997). PSA expression may be related
to response to endocrine therapy.
In the present study of 1516 breast cancer cytosols, the median
PSA level was 20.3 pg mg–1 protein. This level is identical to that
reported in a series of 199 patients (Yu et al, 1996a), but slightly
higher than the observed 15 pg mg–1 protein determined in 1275
breast tumours which, however, were pooled from separate studies
(Yu et al, 1994a). The slightly higher PSA levels in the present
study cannot have resulted from the use of different assays to
measure PSA because both series of tumours were analysed by the
same method. One reason for the observed variation in PSA levels
in the different series of samples could be the different compositionPSA in recurrent breast cancer 893
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of the buffers which were used to prepare the tumour cytosols (Yu
et al, 1994a, 1995a, 1996a). Despite the distinct patient groups and
some technical dissimilarities, the data shown in the present study
confirm those which have been published previously regarding the
relationship of PSA with patient and tumour characteristics. These
relationships are the observed higher PSA levels in younger
patients (Yu et al, 1994a, 1996a), in smaller tumours (Yu et al,
1995a), and in steroid hormone receptor-positive tumours, espe-
cially in those which were positive for PgR (Yu et al, 1994a, 1995a;
Levesque et al, 1995b). In analogy with a previous study (Yu et al,
1995a), we found no association between PSA and nodal status.
In the two studies on the prognostic relevance of PSA published
so far, involving 174 and q53 primary breast cancer patients, a cut-
off point of 30 pg mg–1 protein was chosen to classify breast
tumours as PSA positive and negative (Yu et al, 1995a, 1998).
Patients with PSA-positive tumours showed an improved relapse-
free survival in both Cox univariate and multivariate regression
analyses (Yu et al, 1995a, 1998). In our large study, however, there
was no statistically significant association between the levels of
PSA in the primary tumour and the rate of relapse. We, therefore,
considered it unjustified to search for a cut-off point. To enable
analysis of PSA as a categorical variable, we have divided the
patients in four subgroups with an equal number of patients (quar-
tiles), based on the levels of PSA. For comparison of our data with
those published previously (Yu et al, 1995a, 1998), with 27% and
24% respectively, of the patients classified as positive, our patients
in the fourth quarter group could be considered as PSA positive.
Indeed, these patients showed an improved survival in univariate
analysis, but after correction for age the relationship between PSA
and age was no longer statistically significant. In contrast with the
previous studies (Yu et al, 1995a, 1998), high levels of PSA were
not significantly associated with a decreased relapse rate.
Compared with the study of Yu et al (1995a, 1998), we had a
different group of patients, a longer follow-up period (median 85
vs 33 and 73 months) and, as a consequence, a higher proportion
of patients who relapsed (47% vs 24% and 21%).
The present study is the first to show that high levels of PSA in
primary breast tumours are associated with a poor response and a
short duration of response to first-line tamoxifen therapy in recur-
rent disease. The association of high PSA expression with poor
patient outcome was independent of age/menopausal status, disease-
free interval between primary surgery and the occurrence of relapse,
site of metastasis, adjuvant chemotherapy, and ER and PgR status. It
is puzzling why a factor which is positively related to steriod
hormone receptors is associated with a poor response and survival
on tamoxifen therapy in recurrent disease. The association of PSA
with poor response and survival in recurrent breast cancer may be
due to its intrinsic biological properties of being a serine protease. In
other words, PSA, like the serine protease urokinase-type plas-
minogen activator (uPA) (Foekens et al, 1995), may increase tumour
growth by enzymatic activation of specific growth factor (receptor)-
binding protein pathways. In its active form, uPA is able to convert
plasminogen into plasmin. Plasmin can subsequently directly
degrade components of the extracellular matrix, and furthermore
can activate type-IV collagenase. These activated enzyme systems,
in which uPA is considered to play a key role, lead to the processes
of tumour cell invasion and metastasis (Danø et al, 1985; Mignatti
and Rifkin, 1993; Andreasen et al, 1997). Almost a decade ago, a
high level of uPA activity in primary breast tumours was found to be
associated with an early relapse (Duffy et al, 1988). There is now a
profound body of evidence that a higher level of uPA protein, which
in contrast to PSA, is found more frequently in ER- and PgR-nega-
tive tumours (Jänicke et al, 1990), is associated with poor prognosis
in primary breast cancer (Jänicke et al, 1990; Foekens et al, 1992;
reviewed by: Duffy, 1996; Andreasen et al, 1997; Schmitt et al,
1997), and also in a broad variety of other cancer types (Duffy,
1996). In analogy to uPA, the relationship of PSA to a poor response
to tamoxifen therapy, which does not affect PSA expression in vitro
(Zarghami et al, 1997), may, for example, be due to a local increase
in the concentration of bioavailable IGFs by cleaving IGFBPs
(Cohen et al, 1992, 1994; Figueroa and Yee, 1992; Kanety et al,
1993) through tumour cell-secreted PSA. The free IGFs, abundantly
present around the tumour cells because of the focal action of
secreted PSA, are potent mitogens for breast cancer cells (Osborne
et al, 1989; Cullen et al, 1990). They may disturb the balance and
abolish the growth inhibitory effects induced by tamoxifen, despite
a reduction in total serum levels of IGFs (Pollak et al, 1990;
Lonning et al, 1992; Yee et al, 1994).
Our study suggests that a low tumour level of PSA is associated
with an improved rate and duration of response, and a prolonged
progression-free and overall survival after start of tamoxifen therapy
for metastatic disease. Thus, low tumour levels of PSA may identify
patients who will respond better to first-line tamoxifen therapy. In
contrast, patients with a high tumour level of PSA might benefit
from chemotherapy. However, suggestions for the most promising
systemic treatment for the individual breast cancer patient based on
the tumour level of PSA awaits confirmatory studies including those
patients who received chemotherapy as well, preferably within
prospective trials.
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